In particular in breast cancer, uPA and PAI-1 have been validated as predictive or prognostic biomarkers and in vivo experiments emphasise anti-tumour effects when uPA-uPAR interactions or uPA alone were inhibited [27–30]. This evidence concerns the gene PLAU and breast carcinoma.